Ginkgo Bioworks
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Below its 200-day average or in the bottom third on momentum — the strategy is out of it.
- Signal has read SELL for 3 days.
- Recent price momentum is +1.3% on average (3-month/1-year).
- Main-fund capital flow has been a net inflow over the last 45 sessions.
- Short interest has risen to 14.1% of float.
- Analyst tilt is Sell.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is above the 60-day average, a short-term uptrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Performance
Key statistics
Price & volume
- Prev close
- 8.20
- Open
- 7.93
- Day range
- 7.38 - 8.29
- Avg price
- 7.67
- Volume
- 2.51M
- Turnover
- 19.26M
- Turnover ratei
- 4.81%
- Volume ratioi
- 0.96
- Amplitudei
- 11.10%
- 52-week rangei
- 5.37 - 18.22
Valuation
- P/Ei
- -1.32
- P/E (TTM)i
- -1.79
- P/Bi
- 1.23
- EPSi
- -5.64
- Book value / shi
- 6.06
- Net profit
- -365.61M
- Net assets
- 392.65M
Share structure
- Market cap
- 483.59M
- Float capi
- 389.24M
- Shares out
- 64.83M
- Float sharesi
- 52.18M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- --
59.1% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
+5.84M net over the window
Short interest
- Shares short
- 9.49M
- % of floati
- 14.09%
- Days to coveri
- 3.85
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of Ginkgo Bioworks (DNA)?
Ginkgo Bioworks last traded at 7.46. This page shows a periodic quote snapshot. Check the displayed quote time.
What is Ginkgo Bioworks's market cap?
About 483.59M.
What is the P/E ratio of Ginkgo Bioworks?
The trailing twelve-month P/E is -1.79. The Valuation tab shows it against the stock's own five-year range.
Does Ginkgo Bioworks pay a dividend?
Ginkgo Bioworks does not currently pay a regular dividend.
Is Ginkgo Bioworks a buy according to analysts?
The consensus of 1 analysts is a Sell rating, with an average 12-month price target of 5.00, which implies 33.0% downside from the current price. This is not investment advice.
What is Ginkgo Bioworks's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Ginkgo Bioworks a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.
Quote time 2026-11-20 19:58:34 · For reference only, not investment advice and not tailored to your situation.
Ginkgo Bioworks discussion 0 comments